<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Oestrogens: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int636-oestrogens.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int636-oestrogens.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int636-oestrogens.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int634-isosorbide-mononitrate.htm" title="Previous: Isosorbide Mononitrate">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int640-estradiol.htm" title="Next: Estradiol">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Oestrogens</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Oestrogens</strong> has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>ACE inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>alpha-blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>angiotensin-II receptor antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise antidepressant effect of</span> <span>tricyclics</span> <span>(but side-effects of <span>tricyclics</span>  possibly increased due to increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int264-antidiabetics.htm">Antidiabetics</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypoglycaemic effect of</span> <span>antidiabetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int293-antifungals-imidazole.htm">Antifungals, Imidazole</a></td><td><p><span>anecdotal reports of contraceptive failure when </span> <span>oestrogens</span> <span>given with</span> <span>imidazoles</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td class="cAI"><p><span>possible contraceptive failure of hormonal contraceptives containing </span> <span>oestrogens</span> <span>when given with</span> <span>aprepitant</span> <span>(alternative contraception recommended)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>possible contraceptive failure of hormonal contraceptives containing </span> <span>oestrogens</span> <span>when given with</span> <span>boceprevir</span> <span>(alternative contraception recommended)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span>possible contraceptive failure of hormonal contraceptives containing </span> <span>oestrogens</span> <span>when given with</span> <span>bosentan</span> <span>(alternative contraception recommended)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>oestrogens</span> <span>possibly increase plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>clonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span>oral contraceptives containing </span> <span>oestrogens</span> <span>increase plasma concentration of</span> <span>corticosteroids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td><p><span></span> <span>oestrogens</span> <span>may enhance or reduce anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td><p><span></span> <span>oestrogens</span> <span>possibly increase plasma concentration of</span> <span>diazepam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise diuretic effect of</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1153-eslicarbazepine.htm">Eslicarbazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>eslicarbazepine</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int291-griseofulvin.htm">Griseofulvin</a></td><td><p><span>anecdotal reports of contraceptive failure and menstrual irregularities when </span> <span>oestrogens</span> <span>given with</span> <span>griseofulvin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>hydralazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td class="cAI"><p><span></span> <span>oestrogens</span> <span>reduce plasma concentration of</span> <span>lamotrigine</span> <span>—consider increasing dose of <span>lamotrigine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1114-melatonin.htm">Melatonin</a></td><td><p><span></span> <span>oestrogens</span> <span>increase plasma concentration of</span> <span>melatonin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>methyldopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>minoxidil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int847-modafinil.htm">Modafinil</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>modafinil</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>moxonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>nelfinavir</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>nevirapine</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>nitrates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int900-oxcarbazepine.htm">Oxcarbazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>oxcarbazepine</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int223-phenindione.htm">Phenindione</a></td><td class="cAI"><p><span></span> <span>oestrogens</span> <span>antagonise anticoagulant effect of</span> <span>phenindione</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int199-rifamycins.htm">Rifamycins</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>rifamycins</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>ritonavir</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int686-ropinirole.htm">Ropinirole</a></td><td><p><span></span> <span>oestrogens</span> <span>increase plasma concentration of</span> <span>ropinirole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1102-rufinamide.htm">Rufinamide</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>rufinamide</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span></span> <span>oestrogens</span> <span>increase plasma concentration of</span> <span>selegiline</span> <span>—manufacturer of <span>selegiline</span> advises avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span></span> <span>oestrogens</span> <span>antagonise hypotensive effect of</span> <span>sodium nitroprusside</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int848-somatropin.htm">Somatropin</a></td><td><p><span></span> <span>oestrogens</span> <span>(when used as oral replacement therapy) may increase dose requirements of</span> <span>somatropin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>contraceptive effect of </span> <span>oestrogens</span> <span>reduced by</span> <span>St John's wort</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int292-terbinafine.htm">Terbinafine</a></td><td><p><span>occasional reports of breakthrough bleeding when </span> <span>oestrogens</span> <span>(used for contraception) given with</span> <span>terbinafine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>oestrogens</span> <span>increase plasma concentration of</span> <span>theophylline</span> <span>(consider reducing dose of <span>theophylline</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int935-thyroid-hormones.htm">Thyroid Hormones</a></td><td><p><span></span> <span>oestrogens</span> <span>may increase requirements for</span> <span>thyroid hormones</span> <span>in hypothyroidism</span>  </p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td><p><span></span> <span>oestrogens</span> <span>possibly increase plasma concentration of</span> <span>tizanidine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int285-topiramate.htm">Topiramate</a></td><td class="cAI"><p><span>metabolism of </span> <span>oestrogens</span> <span>accelerated by</span> <span>topiramate</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td class="cAI"><p><span>possible reduction in contraceptive effect of </span> <span>oestrogens</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td><p><span></span> <span>oestrogens</span> <span>increase plasma concentration of</span> <span>voriconazole</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Estradiol</strong> belongs to <strong>Oestrogens</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span> <span>estradiol</span> <span>increased by</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr></tbody></table><p><strong>Estriol</strong> belongs to <strong>Oestrogens</strong> but has no specific interaction information.</p><p><strong>Estrone</strong> belongs to <strong>Oestrogens</strong> but has no specific interaction information.</p><p><strong>Ethinylestradiol</strong> belongs to <strong>Oestrogens</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma concentration of </span> <span>ethinylestradiol</span> <span>increased by</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>plasma concentration of </span> <span>ethinylestradiol</span> <span>increased by</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1108-colesevelam.htm">Colesevelam</a></td><td><p><span>absorption of </span> <span>ethinylestradiol</span> <span>reduced by</span> <span>colesevelam</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </p></div></td></tr><tr><td><a href="bnf_int960-etoricoxib.htm">Etoricoxib</a></td><td><p><span>plasma concentration of </span> <span>ethinylestradiol</span> <span>increased by</span> <span>etoricoxib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td><p><span>plasma concentration of </span> <span>ethinylestradiol</span> <span>increased by</span> <span>rosuvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>ethinylestradiol</span> <span>possibly increases plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ethinylestradiol</span> <span>possibly reduced by</span> <span>telaprevir</span> <span>—manufacturer of <span>telaprevir</span> advises additional contraceptive precautions</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span></span> <span>ethinylestradiol</span> <span>possibly reduces plasma concentration of</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Mestranol</strong> belongs to <strong>Oestrogens</strong> but has no specific interaction information.</p><p><strong>Oestrogens, conjugated</strong> belongs to <strong>Oestrogens</strong> but has no specific interaction information.</p></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int640-estradiol.htm" title="Estradiol">Estradiol</a></li><li><a href="bnf_int641-estriol.htm" title="Estriol">Estriol</a></li><li><a href="bnf_int642-estrone.htm" title="Estrone">Estrone</a></li><li><a href="bnf_int638-ethinylestradiol.htm" title="Ethinylestradiol">Ethinylestradiol</a></li><li><a href="bnf_int639-mestranol.htm" title="Mestranol">Mestranol</a></li><li><a href="bnf_int643-oestrogens-conjugated.htm" title="Oestrogens, conjugated">Oestrogens, conjugated</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int634-isosorbide-mononitrate.htm">Previous: Isosorbide Mononitrate</a> | <a class="top" href="bnf_int636-oestrogens.htm#">Top</a> | <a accesskey="]" href="bnf_int640-estradiol.htm">Next: Estradiol</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>